Securities code: Shanghai Pharmaceuticals Holding Co.Ltd(601607) securities abbreviation: Shanghai Pharmaceuticals Holding Co.Ltd(601607) No.: pro 2022013
Shanghai Pharmaceuticals Holding Co.Ltd(601607)
Announcement on the reply to the feedback (Revised Draft) of the notice of the CSRC on the first feedback on the examination of administrative licensing projects
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents.
Shanghai Pharmaceuticals Holding Co.Ltd(601607) (hereinafter referred to as “the company”) received the notice of the CSRC’s feedback on the examination of administrative licensing projects (hereinafter referred to as “the notice of feedback”) issued by the China Securities Regulatory Commission (hereinafter referred to as “the CSRC”) on September 6, 2021. For details, see the company’s announcement Lin 2021078. According to the requirements of the feedback notice, the company has carefully studied and replied to the questions raised in the feedback together with the intermediary. For the specific contents, see the company’s publication on the website of Shanghai Stock Exchange on September 30, 2021（ http://www.sse.com.cn./ ）Reply to the feedback on the application documents for A-Shares of non-public development banks in Shanghai Pharmaceuticals Holding Co.Ltd(601607) 2021.
According to the further review opinions of the CSRC, the company, together with relevant intermediaries, supplemented and revised the reply contents of the feedback opinions. For details, please refer to the website of Shanghai Stock Exchange published by the company on the same day（ http://www.sse.com.cn./ ）Reply report on feedback on application documents of non-public Development Bank A shares in Shanghai Pharmaceuticals Holding Co.Ltd(601607) 2021 (Revised Version).
The company’s non-public offering of A-Shares still needs to be approved by the CSRC, and whether it can be approved is still uncertain. The company will fulfill the obligation of information disclosure in time according to the review progress of the matter by the CSRC. Please pay attention to the investment risks.
It is hereby announced.
Shanghai Pharmaceuticals Holding Co.Ltd(601607)
Board of directors
March 8, 2022
